Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 Infection With Extended-Duration Nirmatrelvir-Ritonavir Among Outpatients With Hematologic Cancer
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
Persistent symptomatic coronavirus disease 2019 (COVID-19) is a distinct clinical entity among patients with hematologic cancer and/or profound immunosuppression. The optimal medical management is unknown. We describe 2 patients who had symptomatic COVID-19 for almost 6 months and were successfully treated in the ambulatory setting with extended courses of nirmatrelvir-ritonavir.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Open forum infectious diseases - 10(2023), 6 vom: 02. Juni, Seite ofad306 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Catherine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Extended nirmatrelvir-ritonavir |
|---|
| Anmerkungen: |
Date Revised 02.07.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ofid/ofad306 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358845300 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358845300 | ||
| 003 | DE-627 | ||
| 005 | 20231226075619.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ofid/ofad306 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM358845300 | ||
| 035 | |a (NLM)37383248 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Catherine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 Infection With Extended-Duration Nirmatrelvir-Ritonavir Among Outpatients With Hematologic Cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.07.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a Persistent symptomatic coronavirus disease 2019 (COVID-19) is a distinct clinical entity among patients with hematologic cancer and/or profound immunosuppression. The optimal medical management is unknown. We describe 2 patients who had symptomatic COVID-19 for almost 6 months and were successfully treated in the ambulatory setting with extended courses of nirmatrelvir-ritonavir | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a extended nirmatrelvir-ritonavir | |
| 650 | 4 | |a hematologic cancer | |
| 650 | 4 | |a persistent COVID-19 | |
| 700 | 1 | |a Yoke, Leah H |e verfasserin |4 aut | |
| 700 | 1 | |a Bhattacharyya, Pooja |e verfasserin |4 aut | |
| 700 | 1 | |a Cassaday, Ryan D |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Guang-Shing |e verfasserin |4 aut | |
| 700 | 1 | |a Escobar, Zahra Kassamali |e verfasserin |4 aut | |
| 700 | 1 | |a Ghiuzeli, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a McCulloch, Denise J |e verfasserin |4 aut | |
| 700 | 1 | |a Pergam, Steven A |e verfasserin |4 aut | |
| 700 | 1 | |a Roychoudhury, Pavitra |e verfasserin |4 aut | |
| 700 | 1 | |a Tverdek, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Schiffer, Joshua T |e verfasserin |4 aut | |
| 700 | 1 | |a Ford, Emily S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Open forum infectious diseases |d 2014 |g 10(2023), 6 vom: 02. Juni, Seite ofad306 |w (DE-627)NLM243576811 |x 2328-8957 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:6 |g day:02 |g month:06 |g pages:ofad306 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ofid/ofad306 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 6 |b 02 |c 06 |h ofad306 | ||